Feng Zhang
Research Subjects
Feng Zhang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Aiping Wang1 shared publication
- Bin Yu
Shaoxing Maternity and Child Health Care Hospital, Shaoxing, China
1 shared publication - Hai-Gang Ding
Shaoxing People’s Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, China
1 shared publication - Hai-Tao Pan
Shaoxing Maternity and Child Health Care Hospital, Shaoxing, China
1 shared publication - Lu Zhao
Jiangsu Key Laboratory of Geriatric Precision Medicine and Aging Intervention Xuzhou Medical University Xuzhou Jiangsu China
1 shared publication - Ming ni1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 84 (1) , 45-53
Oral Transport Characteristics and the Effects of Trigonelline With Contrast-Induced Acute Kidney Injury In Vivo and In Vitro
Background: Contrast-induced acute kidney injury (CI-AKI) and associated vascular endothelial damage represent significant clinical complications, yet effective preventive strategies remain limited. This study aims to investigate the protective efficacy of trigonelline against these injuries and elucidate its intestinal transport mechanisms to support its potential as a therapeutic agent. Methods: In this study, a contrast-induced acute kidney injury model was established in mice by tail vein injection of iohexol to investigate the kidney protective effects of trigonelline. Using a Caco-2 intestinal epithelial cell monolayer model, the transport characteristics of trigonelline and the involvement of potential transporters were systematically evaluated. Results: The concentration gradients of trigonelline used in the experiments showed no cytotoxic effects on Caco-2 cells. Trigonelline exhibited moderate intestinal absorption. The efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) were involved in the intestinal transport of trigonelline. Crucially, in the in vivo mouse model, trigonelline treatment significantly ameliorated iohexol-induced renal injury, evidenced by a dose-dependent reduction in serum creatinine and BUN levels, and a decrease in inflammatory cytokines (IL-6, TNF-α). Histopathological analysis confirmed that trigonelline effectively mitigated renal tubular necrosis and interstitial inflammation. Conclusion: The transport characteristics and potential vascular protective effects of trigonelline provide valuable insights for the design and development of therapeutic agents aimed at preventing contrast agent-induced vascular injury, and also contribute to a deeper understanding of the pharmacological activity of trigonelline.
- 17 June 2026
- Published by Polish Pharmaceutical Society in Acta Poloniae Pharmaceutica - Drug Research
- Vol. 84 (1) , 45-53
Open AccessOral Transport Characteristics and the Effects of Trigonelline With Contrast-Induced Acute Kidney Injury In Vivo and In Vitro
Background: Contrast-induced acute kidney injury (CI-AKI) and associated vascular endothelial damage represent significant clinical complications, yet effective preventive strategies remain limited. This study aims to investigate the protective efficacy of trigonelline against these injuries and elucidate its intestinal transport mechanisms to support its potential as a therapeutic agent. Methods: In this study, a contrast-induced acute kidney injury model was established in mice by tail vein injection of iohexol to investigate the kidney protective effects of trigonelline. Using a Caco-2 intestinal epithelial cell monolayer model, the transport characteristics of trigonelline and the involvement of potential transporters were systematically evaluated. Results: The concentration gradients of trigonelline used in the experiments showed no cytotoxic effects on Caco-2 cells. Trigonelline exhibited moderate intestinal absorption. The efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) were involved in the intestinal transport of trigonelline. Crucially, in the in vivo mouse model, trigonelline treatment significantly ameliorated iohexol-induced renal injury, evidenced by a dose-dependent reduction in serum creatinine and BUN levels, and a decrease in inflammatory cytokines (IL-6, TNF-α). Histopathological analysis confirmed that trigonelline effectively mitigated renal tubular necrosis and interstitial inflammation. Conclusion: The transport characteristics and potential vascular protective effects of trigonelline provide valuable insights for the design and development of therapeutic agents aimed at preventing contrast agent-induced vascular injury, and also contribute to a deeper understanding of the pharmacological activity of trigonelline.